Hourly refreshWed, Oct 28, 2026

Press Release Database

Recent press releases, indexed by topic.
Topic

Healthcare

3,531 press releases in English indexed under healthcare.

Clear all filters
Keywords, dates and language
Sources
up to 10
Newswires (50)
Company newsrooms (91)
Companies
Releases linked to any of up to 10 companies
AllFinanceCryptoAISaaSHealthcareReal estateEnergyRetailAutomotiveGamingMediaEducation
+ 33 more topics
DownloadExcelTXT
Finance · Healthcare

Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff Deadline

SAN FRANCISCO, Sept. 7, 2026 -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities practice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the...

Sep 7 · 17:22PR Newswire
Finance · Healthcare

Deadline Alert: Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

LOS ANGELES, Sept. 07, 2026 -- Glancy Prongay Wolke & Rotter LLP  reminds investors of the upcoming October 20, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) securities between January 13, 2025 and January 29, 2026 inclusive (the “Class Period”).

Sep 7 · 17:20GlobeNewswire
Finance · Healthcare

REGN 1-WEEK DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit

SAN FRANCISCO, Sept. 7, 2026 -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to...

Sep 7 · 17:19PR Newswire
Healthcare · Biotech & pharma

Zealand Pharma - Transactions related to share buy-back program (week 36, 2026)

Company announcement No. 46 / 2026

Sep 7 · 15:00GlobeNewswire
Healthcare · Biotech & pharma

Pharma Equity Group A/S – Challenge to Arbitral Award

About Pharma Equity Group A/S

Sep 7 · 14:43GlobeNewswire
Healthcare · Biotech & pharma

Injectable Drug Delivery Market Forecast: USD 1,034.78 Billion by 2030 – MarketsandMarkets™

Delray Beach, FL, Sept. 07, 2026 -- MarketsandMarkets™ projects the global injectable drug delivery market will grow from USD 690.23 billion in 2025 to USD 1,034.78 billion by 2030, at a CAGR of 8.4% during the forecast period. Market growth is fueled by the rising prevalence of chronic diseases such as diabetes, cancer, cardiovascular diseases, and autoimmune disorders, increasing demand for biologics, advancements in injectable formulations, and the growing adoption of patient-friendly drug delivery devices including prefilled syringes, autoinjectors, pen injectors, wearable injectors, and needle-free systems.

Sep 7 · 14:30GlobeNewswire
Healthcare

Form 8.3 - Advanced Medical Solutions Group plc - Octopus Investments

FORM 8.3

Sep 7 · 11:54GlobeNewswire
Healthcare · Retail

Withings Becomes Official Connected Health Supplier of the France Basketball National Teams

BOSTON, Sept. 7, 2026 -- The Fédération Française de BasketBall (FFBB) and Withings, the French company behind the world's first Wi-Fi smart scale and the largest consumer connected-health ecosystem in the world, today announced a multi-year partnership, making Withings the...

Sep 7 · 11:00PR Newswire
Finance · Healthcare

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026

COPENHAGEN, Denmark, Sept. 07, 2026 -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for Paediatric Endocrinology (ESPE) being held September 8-10, 2026, in Marseille, France. Updates will include a podium presentation of the first sentinel cohort data from the pivotal reACHin Trial of TransCon CNP (navepegritide) in infants with achondroplasia aged 0 to <2 years.

Sep 7 · 11:00GlobeNewswire
Healthcare

Form 8.5 (EPT/RI)-Advanced Medical Solutions Group Plc

FORM 8.5 (EPT/RI)

Sep 7 · 08:45GlobeNewswire
Healthcare

Samsung Medison Expands Women’s Health Diagnostic Portfolio With Launch of Premium Ultrasound ‘HERA Z10’

Samsung Medison launched its premium obstetrics and gynecology (OB/GYN) ultrasound diagnostic system, the HERA Z10. Alongside the flagship HERA Z20, the new system officially completes the HERA Z Series (Z20 & Z10) lineup. With global trends showing an increase in maternal age and pregnancy-related complications, precision imaging for prenatal diagnostics and rapid clinical decision-making have […]

Sep 7 · 03:18Samsung
Healthcare

Rezubio Announces FDA and NMPA IND Clearances and First Cohort Dosing of RZ-520, a Novel Inhaled Therapy for Chronic Respiratory Diseases

Rezubio announces clearances of FDA and NMPA and first participant dosing of RZ-520

Sep 7 · 01:19GlobeNewswire